The Quorum Sensing Peptides PhrG, CSP and EDF Promote Angiogenesis and Invasion of Breast Cancer Cells In Vitro

Bart De Spiegeleer1 *, Frederick Verbeke1, Matthias D’Hondt1, An Hendrix2, Christophe Van De Wiele3, Christian Burvenich4, Kathelijne Peremans5, Olivier De Wever2, Marc Bracke2, Evelien Wynendaele1

1 Drug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium, 2 Department of Radiation Oncology and Experimental Cancer Research, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium, 3 Department of Radiology and Nuclear Medicine, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium, 4 Comparative Physiology and Biometrics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium, 5 Department of Medical Imaging, Medicine and Clinical Biology of Small Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium

* Bart.DeSpiegeleer@UGent.be

Abstract

The role of the human microbiome on cancer progression remains unclear. Therefore, in this study, we investigated the influence of some quorum sensing peptides, produced by diverse commensal or pathogenic bacteria, on breast cancer cell invasion and thus cancer outcome. Based on microscopy, transcriptome and Chick Chorioallantoic Membrane (CAM) analyses, four peptides (PhrG from B. subtilis, CSP from S. mitis and EDF from E. coli, together with its tripeptide analogue) were found to promote tumour cell invasion and angiogenesis, thereby potentially influencing tumour metastasis. Our results offer not only new insights on the possible role of the microbiome, but also further opportunities in cancer prevention and therapy by competing with these endogenous molecules and/or by modifying people’s life style.

Introduction

To date, cancer figures among the leading causes of death in human societies worldwide. Next to a person’s genetic factors and carcinogens exposure, the human microbiome recently gathered great attention in tumour development as well [1]. Helicobacter pylori, a commensal of the human stomach in almost half of the world’s population, was found to cause gastric adenocarcinoma through the CagA and VacA toxins [2]. Colon cancer on the other hand can be influenced by several gut bacteria, producing reactive oxygen/nitrogen species or bacterial toxins (e.g. Colibactin from Escherichia coli) [3, 4].

The vast majority of bacteria inhabit the human intestine, with as many as 10^{12} cells per gram of the average human faeces. Besides, other habitats like skin, mouth, vagina and mammary gland are occupied as well, next to the occasional presence in the blood (bacteraemia or
The breast milk in the mammary gland is a continuous source of commensal, mutualistic and potentially probiotic bacteria to the infant gut, containing *i.a. lactic acid bacteria, Staphylococcus* and *Streptococcus* species [5]. In contrast to the breast milk, the human breast tissue was originally thought to be sterile. However, given the nutrient rich fatty composition of the female breast, together with the blood and lymphatic vasculature, and the diffuse location of the lobules and ducts, bacteria can spread within the mammary glands, resulting in a breast tissue microbiome. Urbaniak *et al.* indeed found a higher abundance of *Proteobacteria, Firmicutes* (specifically the class Bacilli) and *Actinobacteria* in the breast tissue, while no signs or symptoms of infection were assigned [6]. These results, serving as a first indication, are eagerly waiting to be confirmed and further investigated towards its pathophysiological role.

Bacteria communicate with each other by the use of signalling molecules in a cell-density dependent manner, a process called ‘quorum sensing’. The signalling molecules differ between the groups of bacteria: while Gram-negative bacteria predominantly use *N*-acyl homoserine lacton (AHL) molecules, the Gram-positive bacteria communicate by the use of oligopeptides; both Gram-positive and Gram-negative bacteria synthesize autoinducer-2 (AI-2) signalling molecules. The quorum sensing process was found to be activated *in vivo* as both the quorum sensing end products (*e.g.* biofilms or toxins) and signalling molecules were detected in different areas of the human body. Bacterial biofilms that can be produced after quorum sensing pathway activation can be detected at diverse physiological sites: *e.g.* dental plaques produced by *Streptococcus mitis* or *Lactobacillus* species, as well as nosocomial infections with vascular grafts or urinary catheters after biofilm formation by *Staphylococci* or *Escherichia coli*, were observed [7]. Moreover, *N*-acyl homoserine lacton signalling molecules were detected in human biological samples as well, including sputum, faeces and saliva [8, 9]. Although thus not yet investigated, it is very likely that also quorum sensing peptides are found in the human body, at their site of origin or distributed throughout the human body via the blood circulation.

Despite the increasing evidence of the human microbiome influencing health, up till now, no research has been performed describing the role of quorum sensing peptides on tumour progression. However, important parallels are seen between the bacterial quorum sensing mechanisms and the biochemical and biological mechanisms metastatic cancer cells use to function as a society of malignant cancer cells. The process of biofilm formation has many of the characteristics of metastatic colonization, including motility of cells towards appropriate surfaces, attachment and interaction of cells with each other, surface adhesion and colonization, formation of a complex, heterogeneity, *...* [10]. Seen these correlations, we hypothesized that cancer cell behaviour can be influenced as well by the quorum sensing signalling peptides, produced by the bacteria of the microbiome. The increasing incidence of breast cancer in women in both developed and developing countries [11], together with the very recent identification of different Gram-positive bacteria in the breast tissue [6], excited the research in the influence of quorum sensing peptides on breast cancer cell behaviour. To this end, we investigated their effect on the human epithelial breast cancer cell line MCF-7/AZ, in order to explain (part) of the microbiome-cancer relationship.

**Materials and Methods**

**Cell culture**

The epithelial breast adenocarcinoma cell line MCF-7/AZ (ATCC CCL-224) was grown in high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% (V/V) foetal bovine serum (FBS), 1% (w/V) L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (all from Invitrogen/GIBCO, Gent, Belgium) in a humidified atmosphere of 10% CO₂ at 37°C.
Caco-2 cells, originating from a human colorectal carcinoma, were cultured in high-glucose Dulbecco's Modified Eagle's Medium (DMEM) with L-glutamine, supplemented with 10% (V/V) fetal bovine serum (FBS), 1% of nonessential amino acids (100x), 100 U/ml penicillin and 100 μg/ml streptomycin (all from Invitrogen/GIBCO, Gent, Belgium) in a humidified atmosphere of 10% CO₂ at 37°C.

Collagen type I invasion assay

Morphology changes of MCF-7/AZ cells were investigated using previously described methods [12]. In brief, 10,000 cells were seeded per well in a 48-well plate, containing 150 μl of collagen type I gel per well, thereby investigating cell morphology 24 hours post-treatment (Leica DMI3000B phase contrast microscope). Peptide solutions (Table 1) (> 80% purity; all from GL Biochem, Shanghai, China) were prepared using ultrapure water and DMSO, obtaining final peptide concentrations of 1 μM (maximum 0.05% DMSO), 100 nM and 10 nM after 1:10 dilution using growth medium. The placebo sample solely contained ultrapure water; the low DMSO concentration did not influence cell behaviour. Two independent morphology scorings were obtained for each of the 3 replicates; peptides were found positive if collagen invasion or cell-stretching at minimum 2 consecutive concentrations was established. To quantify these visual results, the number of cells containing invasive extensions were counted and compared to the total number of cells in the field.

Human transcriptome array

Cells treated with either EDF, PhrG or CSP were analyzed in duplicate (independent treatment and analysis) for whole transcriptome expression using Affymetrix GeneChip Human Transcriptome Array 2.0 by AROS Applied Biotechnology A/S (Aarhus, Denmark); RNA expression was compared with placebo treated samples. Data analysis was performed using Transcriptome Analysis Console (Affymetrix) and MetaCore (Thompson Reuters) software programs. The microarray data are deposited at AROS Applied Biotechnology under project numbers A2224 and A2080. The microarray data were submitted to ArrayExpress and received accession number E-MTAB-3191.

Chick Chorioallantoic Membrane (CAM) assay

The Chick Chorioallantoic Membrane (CAM) assay was performed as described by Sys et al.: 6 days after (pre-treated, 100 nM) tumour cell transfer to the fertilized eggs, CAM was microscopically scored and histologically examined after H&E staining [13]. For quantification of microscopically observed neovascularisation, an average CAM score was calculated: the number of blood vessels in the 1 mm diameter ring around the 2 mm radius tumour centre was determined [14]. Significant differences were evaluated using the Mann—Whitney U test.

Proteome assay

Protein expression was investigated using the Human XL Oncology Array kit (R&D Systems, Abingdon, United Kingdom), following the instructions of the supplier. In brief, cell lysates were obtained after 24 hours of incubation with PhrG (100 nM) or placebo (water) and 84 different proteins analysed in duplo using spotted capture antibodies, followed by incubation with detection antibodies and chemiluminescent visualization. Membranes are finally exposed to X-ray films for 1–10 minutes. The mean (blank corrected, n = 2) pixel density is calculated using ImageJ software and compared with placebo treatment. Significant differences were evaluated using the independent samples t-test.
Caco-2 permeability assay

For transport studies, Caco-2 cells were seeded at a density of 300,000 cells for each Transwell (Corning Costar, New York, USA) membrane insert filter (0.4 μm pore size, 12 mm filter diameter). Cell culture medium was changed every second day until monolayers were formed (day 21–29); monolayer integrity was evaluated using resistance measurements. Transport experiments were performed in both the apical-to-basolateral and basolateral-to-apical direction in Hanks’ balanced salt solution (HBSS), according to Hubatsch et al. [15]. Peptide solutions (PhrG, EDF and EDF-analogue, each 10 μM in HBSS) were added to the donor compartment and aliquots taken from the receiving solution after 30, 60, 90 and 120 minutes of incubation. Aliquots of the donor solutions after 120 minutes were taken as well for calculation of the mass balance. Atenolol (50 μM) and propranolol (20 μM) were used as the low- and high-permeability control, respectively [16]. Peptide samples were analyzed using UPLC-ESI/MS in selected ion monitoring (SIM, monoisotopic mass of the peptides) mode for the peptide analyte, with limits of detection of 0.56–0.58 pmol/ml. The system consisted of a Waters Acquity H-Class Bio-samples FTN (flow rate set at 0.5 ml/min), Waters Acquity H-Class BioQuaternary Solvent Manager, Waters Acquity H-Class column module (set at 30°C) and Waters Xevo TQ-S, equipped with Waters Empower Pro software version 2 and MassLynx version 4.1 (Waters, Zellik, Belgium). Mixtures of water (0.1% formic acid m/V) and acetonitrile (0.1% formic acid m/V) were used to create appropriate gradients (95% to 80% of water in 3 minutes) and ACQUITY UPLC BEH300 C18 column (1.7 μm, 2.1 x 100 mm dimensions) for analysing the peptide solutions (5 μl injection volume). PepT1 transport (apical-to-basolateral direction) was investigated using the dipeptide LY (10 μM) substrate in combination with the quorum sensing peptide.

The apparent permeability coefficient (P_{app} in cm/s) was determined from the amount of compound transported per time and was calculated as follows (sink conditions): \( P_{app} = \frac{dQ}{dt} / (A x C_0) \), where \( dQ/dt \) is the steady-state flux (pmol/s), A is the surface area of the filter (cm²) and \( C_0 \) is the initial concentration of analyte in the donor chamber (pmol/ml).

Stability in cell medium and human plasma

*In vitro* chemical and metabolic stability was determined in cell medium and human plasma, respectively, using previously described procedures [17]. In brief, 100 μg of peptide was incubated in Krebs-Henseleit buffer pH 7.4 with cell medium/plasma (500 μl) at 37°C while shaking. At predetermined time intervals (i.e., 0, 6 and 24 hours for cell medium; 0, 30 and 120 minutes for plasma), aliquots were immediately transferred into microtubes containing 1:1 volume of 1% (V/V) trifluoroacetic acid solution in water. The enzyme reaction was further stopped by heating the solution at 95°C for 5 minutes. Next, the samples were centrifuged to precipitate the denatured proteins and the supernatant analyzed using UPLC-PDA. Appropriate placebo solutions were similarly prepared. Assuming first-order kinetics, the rate constant \( k \) was obtained from \( \ln(P_t/P_{t0}) = -kt \), from which the half-life was determined as \( t_{1/2} = \ln(2)/k \).

Haemolysis assay

A 10 μM stock solution is prepared for each quorum sensing peptide using water, with or without DMSO for solubility reasons. 40 μl of this stock solution is then diluted with 280 μl of 100 mM sodium phosphate buffer, pH 7.4 to obtain the peptide sample. To prepare the Red Blood Cell (RBC) solution, freshly obtained human blood was centrifuged at 1500 rpm for 15 minutes and the precipitate washed three times using freshly prepared 150 mM NaCl solution. After the final centrifugation step, the precipitate was resuspended into 100 mM sodium phosphate buffer pH 7.4 and mixed by inversion. The RBC solution was then diluted 1 to 10 with the same solvent.
to obtain the diluted RBC solution. To examine the haemolytic properties of the quorum sensing peptides, 320 μl of the peptide sample was mixed with 80 μl of the diluted RBC solution to obtain a final volume of 400 μl and a final peptide concentration of 1 μM. Samples were incubated for 1 hour at 37°C while gently shaking. 100 mM sodium phosphate buffer pH 7.4 and 1% (V/V) Triton X-100 were chosen as the negative and positive control solutions, respectively. Blank solution was obtained by mixing 40 μl of water or aqueous DMSO (60%) with 280 μl of 100 mM sodium phosphate buffer pH 7.4 and 80 μl of diluted RBC solution. After 1 hour of incubation, all samples were centrifuged at 20,000 g for 5 minutes. The absorbance of the supernatant was measured at 405 nm and corrected for the blank absorbance. The percent haemolysis was then calculated using the following equation: \[ \left( \frac{A_{\text{sample}} - A_{\text{blank}}}{A_{\text{positive control}} - A_{\text{blank}}} \right) \times 100 \]

**Results**

To investigate the crosstalk between the quorum sensing peptides produced by the host bacteria and human breast cancer cells, we selected different signalling peptides from the Quorumpeps database (S1 Table) [18]. Four quorum sensing peptides or analogues thereof were consistently (and concentration-dependently) found to induce tumour cell invasion through a type I collagen extracellular matrix: PhrG from *Bacillus subtilis* (EMKIG), a Competence Stimulating Peptide (CSP) from *Streptococcus mitis* (EMRKSNNFFHFLRRI) and Extracellular Death Factor (EDF) from *Escherichia coli* (NNWNN), together with its analogue NWN (Fig. 1). Other peptides (e.g. PhrA (ARNQT) from *Bacillus subtilis* or CSP (ESRLPKIRFD-FIFPRKK) from *Streptococcus mitis*) did not induce invasive characteristics. These biologically active peptides were found to be sufficiently stable in cell medium (Table 1), meaning that the effects, observed after 24 hours of treatment, can be associated with the original peptide structures. These observations of invasive cellular extensions are linked to an induced epithelial-to-mesenchymal transition (EMT), an important process in breast cancer progression and metastasis and the primary cause of breast cancer-related deaths [19, 20].

Up-regulation of the Histone cluster 1 H4 gene (*HIST1H4A-F/H-L*) after EDF treatment, which was observed by our transcriptome expression results (Table 2), assigns tumour progressive characteristics to this quorum sensing peptide. Through its link with β-arrestin 1, EDF induces angiogenesis, thereby promoting the survival of breast cancer cells. Moreover, it promotes cytoskeleton reorganization of breast cancer cells as well through the cofilin pathway, which is crucial for tumour migration [21–23]; these morphologic alterations were already observed in our type I collagen invasion assay. With Notch1 over-expression, a poor clinical outcome of breast cancer is correlated, again promoting angiogenesis and thus tumour progression [24]. Over-expression of the *MTRNR2L2* and *MTRNR2L6* genes, leading to increased synthesis of the Humanin-like proteins 2 and 6 respectively, can be linked to an anti-apoptotic function of the EDF peptide [25]. Finally, up-regulation of *EYA3-IT1* can be associated with increased tumour size and metastasis, due to the tyrosine phosphatase activity of the transcribed proteins, promoting the motility and invasiveness of cancer cells [26].

Gene expression 24 hours post-treatment, compared to placebo samples. Mean fold change is calculated from duplicate samples (cut off: > 1.5 or < -1.5).

The angiogenic properties of the quorum sensing peptides, as postulated by the transcriptome expression results, were confirmed using the Chick Chorioallantoic Membrane (CAM) assay. From Fig. 2, it is clear that all investigated peptides significantly promoted neovascularisation after peptide treatment of the tumour cells, compared to the placebo sample. This recruitment of new blood vessels thereby contributes to the metastasis of tumour cells. Histological evaluation of the membrane confirmed the invasive tumour cell properties through the chorionic layer into the mesoderm, induced by the quorum sensing peptides.
Fig 1. Morphologic changes of non-invasive epithelial MCF-7/AZ cells, induced by quorum sensing peptides at 10 nM. (A) The invasive cellular extensions, observed 24 hours post-treatment with PhrG (EKMIG), CSP (EMRKSNNFFHLRRI), EDF (NNWNN) and the EDF-analogue (NWN), indicate tumour-promoting properties of these quorum sensing peptides. The placebo sample serves as the negative control and TGF-α (0.1 μg/ml) as the positive control. (B) Mean (n = 3) number of cancer cells with induced morphology changes: a significant difference is observed between the PhrG peptide or EDF-analogue and the placebo treatment (* p < 0.05, Mann-Whitney U test). Error bars represent SEM values.

doi:10.1371/journal.pone.0119471.g001
Groups of chorionic epithelial cells thereby indicated an aggressive invasion of MCF-7/AZ cells: the chorion is massively disrupted by the tumour cells, resulting in a collapse of the membrane (black arrowheads in Fig. 3).

The results of quorum sensing peptide induced tumour cell invasion and angiogenesis were confirmed by a protein expression assay (Fig. 4). An increase in Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF) or Hepatocyte Growth Factor Receptor (c-Met/HGFR), seen after quorum sensing peptide treatment, can be linked to the formation of new blood vessels [27, 28]. Second, the induction of epithelial-to-mesenchymal transition (EMT) of the cancer cells after peptide treatment is validated as well: both the Forkhead box protein C2 (FOXC2) and Tyrosine-protein kinase (Axl) expression are significantly induced [29, 30]; an increase in Vimentin expression, together with a decrease in E-cadherin are associated with EMT as well, leading to tumour cell migration and cancer metastasis [31]. Moreover, a decrease in p53 protein expression can be linked to a reduced activation of

| Peptide | Sequence | Cell medium half-life (hours) |
|---------|----------|------------------------------|
| PhrG    | EKMIG    | 160<sup>a</sup>              |
| CSP     | EMRKSNNFFHFLRRRI | 45.84                       |
| EDF     | NWWNN    | 16.19                        |
| EDF-analogue | NWN     | 42.03                        |

The investigated quorum sensing peptides were found highly stable in cell medium.

<sup>a</sup> The calculated half-life is 157.89 hours

| Gene symbol | Fold change | ANOVA p-value | Description                        |
|-------------|-------------|---------------|------------------------------------|
| Upregulated |             |               |                                    |
| MIR548W     | 1.92        | 0.566         | MicroRNA 548w                      |
| HIST1H4A-F/H-L | 1.98      | 0.330         | Histone cluster 1, H4(a-f/h-l)     |
| MTRNR2L2    | 1.69        | 0.010         | MT-RNR2-like 2                     |
| MTRNR2L6    | 1.58        | 0.243         | MT-RNR2-like 6                     |
| RNU2-4P     | 1.59        | 0.011         | RNA, U2 small nuclear 4, pseudogene |
| RNU4-4P     | 1.54        | 0.065         | RNA, U4 small nuclear 4, pseudogene |
| MIR320C2    | 1.67        | 0.076         | MicroRNA 320c-2                    |
| EYA3-IT1    | 1.75        | 0.087         | EYA3 intronic transcript 1         |
| IGLJ4       | 1.58        | 0.011         | Immunoglobulin Lambda Joining 4    |
| SNORD92     | 1.58        | 0.261         | Small Nucleolar RNA, C/D Box 92    |
| FOXP1-IT1   | 1.63        | 0.390         | FOXP1 Intrinsic Transcript 1       |
| MIR635      | 1.65        | 0.024         | MicroRNA 635                       |
| Downregulated |        |               |                                    |
| RN5S217     | -1.88       | 0.127         | RNA, 5S ribosomal 217              |
| FOXQ1       | -1.72       | 0.338         | Forkhead Box Q1                    |
| MAGEB5      | -1.75       | 0.199         | Melanoma Antigen Family B, 5       |
| MIR4718     | -1.64       | 0.401         | MicroRNA 4718                      |
| LOC100128593 | -1.56      | 0.084         | Uncategorized LOC100128593        |

<sup>10.1371/journal.pone.0119471.t001</sup>

<sup>10.1371/journal.pone.0119471.t002</sup>
apoptosis, together with an increased activation of angiogenesis and tumour growth [32]. The induced expression of C-Met/HGFR is associated with an increase of the tumour growth as well [28]. Despite their possible presence in the human breast (cancer) tissue, we investigated the intestinal permeability characteristics of the quorum sensing peptides, produced by commensals...
of the human gut, as well. Intestinal absorption of the peptides thereby strengthens the effects observed on breast cancer cells. EDF (NNWNN), which is synthesized by the human gut commensal *Escherichia coli*, was found to be impermeable through the human epithelial enterocytes under our experimental Caco-2 conditions (i.e. $P_{ab} < 2.9 \times 10^{-9}$ cm/s as LoD = 0.58 nM). However, its tripeptide analogue NWN shows low intestinal permeability kinetics (Fig. 5): a permeability coefficient ($P_{ab}$) of $1.41 \times 10^{-7}$ cm/s was calculated for the apical-to-basolateral transport. The efflux ratio ($P_{ba}/P_{ab}$) of 1.10 is doubled using the PepT1 substrate LY: the $P_{ab}$ decreases to $6.94 \times 10^{-8}$ cm/s, indicative for the active proton-dependent transport mechanism for peptide absorption. In vivo—in vitro correlation studies demonstrated that these in vitro $P_{ab}$ values correspond with the absorption of about 5–10% in humans (in vivo) [15, 33]. Quorum sensing peptide PhrG (EKMIG), produced by *Bacillus subtilis*, only shows very small blood efflux (basolateral-to-apical) transport properties after 120 minutes ($1.37 \times 10^{-8}$ cm/s), without significant Caco-2 influx kinetics (LOD = 0.56 nM, so $P_{ab} < 6.9 \times 10^{-9}$ cm/s).

Once the peptides have reached the blood circulation, they remain sufficiently stable (Table 3), meaning that this pharmacokinetic property will not be the critical parameter for the biological activity observed with these peptides. No haemolytic properties can be assigned to the peptides (1 μM) as well (i.e. percentage of haemolysis < 1%), after a 1 hour incubation period.
Fig 4. Protein expression after PhrG quorum sensing peptide treatment (100 nM) of the MCF-7/AZ cells. Placebo sample serves as negative control. Mean (n = 2, ± SEM) pixel density of some proteins are given after 24 hours of peptide incubation. * p < 0.05; ** p < 0.01; *** p < 0.001 (independent samples t-test).

doi:10.1371/journal.pone.0119471.g004

Fig 5. Intestinal permeability of quorum sensing peptide NWN. (A) Mean (n = 5) apical-to-basolateral transport (i.e. intestinal absorption) of the EDF-analogue (NWN) through a Caco-2 monolayer; (B) mean (n = 6) basolateral-to-apical transport (i.e. blood efflux) of the EDF analogue. Error bars represent SEM values.

doi:10.1371/journal.pone.0119471.g005
Discussion

Our *in vitro* results thus indicate that some quorum sensing peptides promote angiogenesis and induce invasion of human breast cancer cells. Based on these results, different questions related to their biological relevance now arise: (1) Do these quorum sensing peptides reach the breast cancer tissue, (2) Can we inhibit these negative microbiome-related effects, and (3) Does this have consequences for the patient’s life style?

First, very recent investigations have shown that microbial DNA and viable bacterial cells are present in healthy and cancerous breast tissue, thereby indicating that bacteria or their components may influence the local microenvironment. The predominant bacteria in breast tumours were *Escherichia* and *Bacillus* [34]. These findings elicit contradictions with previous insights, where it was assumed that the breast tissue was a sterile location, except for the nipple region; nipple duct contamination with skin flora is generally accepted and plays an important role in breast infection [35]. Clearly, future studies are needed to confirm the presence of a breast tissue microbiome under different personalised conditions and describe the different bacterial species that are present. Next, a thorough exploration of the synthesized quorum sensing peptides in the breast tissue should be performed as well; if found, they can negatively influence the nearby breast cancer tissue.

Quorum sensing peptides, produced by commensal or pathogenic bacteria at distant locations, can reach the breast tissue as well via the blood circulation. *N*-acylhomoserine lactone (AHL) molecules, another group of quorum sensing molecules, are already found in human sputum, faeces and saliva, whereby the last biological sample reflects the systemic AHL concentration [8, 36]. Besides, peptides that are synthesized in the gastrointestinal tract can pass the intestinal barrier as well and consequently reach the blood circulation [37]. Our results indeed indicate that the EDF-analogue NWN, with EDF being synthesized by the gut bacterium *E. coli*, can pass the intestinal barrier, thereby reaching the blood circulation. The PhrG peptide of *Bacillus subtilis*, also a gut bacterium, does not show any absorption from the intestinal lumen. Intestinal permeability is however not limited to these small peptide structures: previous studies have indicated that larger peptides and proteins can also cross the normal intestine in an intact form (e.g. insulin, β-casein) [38–40]. Moreover, the use of permeability enhancers (e.g. bile salts, fatty acids or glycerides) can increase the intestinal absorption of the quorum sensing peptides as well [41]. Quorum sensing peptides can also enter the circulation through the skin or oral mucosa, seen the highly present bacterial population at these sites of the human body [42] and the skin and mouth mucosa permeability-data already described for peptides [43, 44]. In general, the oral mucosa is considered intermediate permeable, situated between the epidermis and the intestinal mucosa [45]. CSP, the quorum sensing peptide synthesized by the oral commensal bacteria *Streptococcus mitis*, thus possibly can reach the

### Table 3. *In vitro* plasma half-life values of quorum sensing peptides.

| Peptide         | Sequence          | Plasma half-life (hours) |
|-----------------|-------------------|--------------------------|
| PhrG            | EKM\(\text{G}\)  | >13<sup>a</sup>          |
| CSP             | EMRKSNNFFHFLRRI  | 8.73                     |
| EDF             | NNWNN            | >13<sup>a</sup>          |
| EDF-analogue    | NWN              | 4.47                     |

The investigated quorum sensing peptides were found sufficiently stable in human plasma, so tumour-promoting properties can be executed at the breast cancer tissue.

<sup>a</sup> The calculated half-life is 13.16 hours

doi:10.1371/journal.pone.0119471.t003
blood circulation after passing the oral mucosa; the same can be observed with the quorum sensing peptide PhrG of *Bacillus subtilis* after passing the skin. This should however be investigated by *in vitro* or *in vivo* permeability assays. Occasionally, bacteria themselves can also be found in the blood circulation: *Bacillus subtilis* and *Streptococcus mitis*, commensals of the gastrointestinal tract or skin and oropharynx, respectively, were found to be present in the blood of cancer patients [6, 46, 47]. PhrG and CSP, when present in the blood circulation, thus can affect the clinical outcome of breast cancer, seen its pro-invasive characteristics on breast cancer cells and angiogenesis-promoting properties. Although thus not yet confirmed, quorum sensing peptides might be available from the blood and influence breast cancer progression.

To answer the second and third question, *i.e.* ‘Can we inhibit these microbiome-related effects and does this have consequences for the patient?’, the *in vivo* functionality of the quorum sensing peptides should be investigated to confirm our obtained *in vitro* results. If the quorum sensing peptides are found to be present *in vivo*, our preliminary *in vitro* findings of prometastatic effects of quorum sensing peptides can open up new perspectives. First, after identification of the tumour target, quorum sensing peptide-based antagonists can be developed to compete with these endogenous molecules for receptor binding. Tumour progression, induced by the quorum sensing peptide, will then be blocked, indicating therapeutic properties for these antagonists. Second, a person’s life style may be adapted to possibly influence the observed bacteria-related effects. As a change in diet can drastically adapt the microbiota composition, and thus the quorum sensing peptide profile, this may possibly have consequences on cancer outcome [48]. Last, inadequate hygienic measures during *e.g.* surgery can induce breast infection as well. Moreover, during lactation, mastitis should be treated carefully to avoid unwanted bacterial infection of the breast tissue as well [49].

The results of this study thus indicate the existence of a crosstalk system between bacteria and breast cancer cells through quorum sensing peptides. More specifically, we showed that these quorum sensing peptides promote breast cancer cell invasion and angiogenesis, and thus that bacteria can potentially influence tumour metastasis. Further research concerning their biological availability should be performed to strengthen these functionality results.

**Supporting Information**

**S1 Table.** List of quorum sensing peptides, repeatedly (*n* = 3) investigated for their effect on tumour cell invasion (*Collagen Type 1 invasion assay*).

(DOCX)

**Acknowledgments**

We thank G. Wagemans and M. De Meulemeester for technical support and assistance with the CAM assays and H&E staining.

**Author Contributions**

Conceived and designed the experiments: BDS EW. Performed the experiments: EW FV. Analyzed the data: BDS MD AH CVDW CB KP ODW MB EW. Contributed reagents/materials/analysis tools: BDS ODW MB. Wrote the paper: BDS EW.

**References**

1. World Health Organization. Cancer health topic, fact sheet number 297; 2014. Available: http://www.who.int/mediacentre/factsheets/fs297/en/

2. Niyaz A, Shivendra T, Nishant N. *Helicobacter pylori*—a seasoned pathogen by any other name. Gut Pathogens. 2009. doi: 10.1186/1757-4749-1-24.
3. Arthur JC, Perez-Chanova E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012; 338: 120–123. doi: 10.1126/science.1224820 PMID: 22903521

4. Schwabe RF, Wang TC. Bacteria Deliver a Genotoxic Hit. Science. 2012; 338: 52–53. doi: 10.1126/science.1229905 PMID: 23042875

5. Cabrera-Rubio R, Collado MC, Laitinen K, Salminen S, Isolauri E, Mira A. The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery. Am J Clin Nutr. 2012; 96: 544–551. doi: 10.3945/ajcn.112.037382 PMID: 22836031

6. Urbaniak C, Cummins J, Brackstone M, Macklaim JM, Gloor GB, Baban CK, et al. Bacterial microbiota of human breast tissue. Appl Environ Microbiol. 2014; 80: 3007–3014. doi: 10.1128/AEM.00242-14 PMID: 24610844

7. Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms: A Common Cause of Persistent Infections. Science. 1999; 284: 1318–1322. PMID: 10334980

8. Kumar A, Pasini P, Daunert S. Detection of bacterial quorum sensing N-acyl homoserine lactones in clinical samples. Anal Bioanal Chem. 2008; 391: 1619–1627. doi: 10.1002/sbce.200700165 PMID: 18408921

9. Erickson DL, Enderby R, Kirkham A, Lefkowitz RJ, DeFea K. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and-2. J Biol Chem. 2004; 279: 55419–55424. PMID: 15489220

10. Burgess DJ. Breast cancer: circulating and dynamic EMT. Nat Rev Cancer. 2013; 13: 148–149. doi: 10.1038/nrc3475 PMID: 23407577

11. Arthur JC, Perez-Chanova E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012; 338: 120–123. doi: 10.1126/science.1224820 PMID: 22903521

12. De Wever O, Hendrix A, De Boeck A, Westbroek W, Braems G, Emami S, et al. Modeling and quantification of cancer cell invasion through collagen type I matrices. Int J Dev Biol. 2010; 54: 887–896. doi: 10.1387/jdb.092948ow PMID: 19757378

13. Sys G, Van Bockstal M, Forsyth R, Balke M, Poffyn B, Uyttendaele D, et al. Tumor grafts derived from sarcoma patients retain tumor morphology, viability, and invasion potential and indicate disease outcomes in the chick chorioallantoic membrane model. Cancer Lett. 2012; 326: 69–78. doi: 10.1016/j.canlet.2012.07.023 PMID: 22841668

14. Cattoor K, Bracke M, Deforce D, De Keukeleire D, Heyerick A. Transport of hop bitter acids across intestinal absorption in Caco-2 monolayers. Nat Protoc. 2007; 2: 2111–2119. PMID: 17853866

15. Cattoor K, Bracke M, De Keukeleire D, Heyerick A. Transport of hop bitter acids across intestinal Caco-2 cell monolayers. J Agric Food Chem. 2010; 58: 4132–4140. doi: 10.1021/jf904079h PMID: 20329731

16. Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B. In vitro metabolic stability of quinolone derivatives. Nucleic Acids Res. 2013; 41: D655–D659. doi: 10.1093/nar/gks1137 PMID: 23180797

17. Wyndaele E, Bronselaer A, Nielandt J, D’Hondt M, Stalmans S, Bracke N, et al. Quorumpeps database; chemical space, microbial origin and functionality of quorum sensing peptides. Nucleic Acids Res. 2013; 41: D655–D659. doi: 10.1093/nar/gks1137 PMID: 23180797

18. Wyndaele E, Bronselaer A, Nielandt J, D’Hondt M, Stalmans S, Bracke N, et al. Quorumpeps database; chemical space, microbial origin and functionality of quorum sensing peptides. Nucleic Acids Res. 2013; 41: D655–D659. doi: 10.1093/nar/gks1137 PMID: 23180797

19. Burgess DJ. Breast cancer: circulating and dynamic EMT. Nat Rev Cancer. 2013; 13: 148–149. doi: 10.1038/nrc3475 PMID: 23407577

20. Tomaskovic-Crook E, Thompson EW, Thiery JP. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 2009. doi: 10.1186/bcr2416.

21. Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y, et al. β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene. 2012; 31: 282–292. doi: 10.1038/onc.2011.238 PMID: 21685944

22. Zoudilova M, Kumar P, Ge L, Wang P, Bokoch GM, DeFea KA. Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. J Biol Chem. 2007; 282: 20634–20646. PMID: 17500066

23. Ge L, Shenoy SK, Lefkowitz RJ, DeFea K. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and-2. J Biol Chem. 2004; 279: 55419–55424. PMID: 15489220

24. Al-Hussaini H, Subramanayam D, Reedijk M, Srithar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther. 2011; 10: 9–15. doi: 10.1158/1535-7163.MCT-10-0677 PMID: 20971825
Bodzioch M, Lapicka-Bodzioch K, Zapala B, Kamysz W, Kiec-Wilk B, Dembinska-Kiec A. Evidence for

25.

Pandey RN, Rani R, Yeo EJ, Spencer M, Hu S, Lang RA, et al. The Eyes Absent phosphatase-transac-

26.

Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological

27.

Regazzo D, Mollé D, Gabai G, Tomé D, Dupont D, Leonil J, et al. The (193

28.

Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R. The role of the c-Met pathway in lung cancer

29.

Dethlefsen L, McFall-Ngai M, Relman DA. An ecological and evolutionary perspective on human-mi-

30.

Jahanfar S, Ng C-J, Teng CL. Antibiotics for mastitis in breastfeeding women. Cochrane Database

31.

Junginger HE. Drug targeting and delivery: concepts in dosage form design. 1st ed. London: CRC

32.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

33.

Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption

34.

Streinu-Cercel A, Jianu DM, Streinu-Cercel O. Breast Ecology Assessment in the Study of Local Micro-

35.

Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epili-

36.

Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, et al. FOXC2 expression links

37.

Chymotrypsin activation of preprorenin by heparin in vitro and in vivo. Thromb Haemost. 2005; 94: 532–7.

38.

Daniel H. Molecular and Integrative Physiology of Intestinal Peptide Transport. Annu Rev Physiol.

39.

Regazzo D, Mollé D, Gabai G, Tomé D, Dupont D, Leonil J, et al. The (193–209) 17-residues peptide of

40.

Antunes F, Andrade F, Ferreira D, Nielsen HM, Sarmento B. Models to predict intestinal absorption of

41.

Taevernier L, Veryser L, Roche N, De Spiegeleer B. Human skin kinetics of cyclic depsipeptide myco-

42.

Aungst BJ, Saitoh H, Burcham DL, Huang S-M, Mousa SA, Hussain MA. Enhancement of the intestinal

43.

Streinu-Cercel A, Jianu DM, Streinu-Cercel O. Breast Ecology Assessment in the Study of Local Micro-

44.

Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. Factors and strategies for improving buccal ab-

45.

Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003; 22: 9030

46.

Junginger HE. Drug targeting and delivery: concepts in dosage form design. 1st ed. London: CRC

47.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

48.

Streinu-Cercel A, Jianu DM, Streinu-Cercel O. Breast Ecology Assessment in the Study of Local Micro-

49.

Jahanfar S, Ng C-J, Teng CL. Antibiotics for mastitis in breastfeeding women. Cochrane Database

50.

Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epili-

51.

Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, et al. FOXC2 expression links

52.

Junginger HE. Drug targeting and delivery: concepts in dosage form design. 1st ed. London: CRC

53.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

54.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

55.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

56.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

57.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

58.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

59.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

60.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients:

61.

Han XY, Kamana M, Rolston KVI. Viridans Streptococci Isolated by Culture from Blood of Cancer Patients: